Adaptive Biotechnologies Corp (NAS:ADPT)
$ 3.65 0.21 (6.1%) Market Cap: 537.89 Mil Enterprise Value: 294.57 Mil PE Ratio: 0 PB Ratio: 1.95 GF Score: 72/100

Adaptive Biotechnologies Corp at Cowen Healthcare Conference (Virtual) Transcript

Mar 02, 2021 / 03:30PM GMT
Release Date Price: $53.11 (-8.26%)
Doug Schenkel
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Everybody, my name is Doug Schenkel. I'm one of the analysts with Cowen focused on the life science and diagnostic tools team. It's my pleasure to welcome you as well as Adaptive Bio to the 41st Annual Cowen and Company Health Care Conference. From the company, it's our pleasure to welcome Chad Robins, the company's Co-Founder and Chief Executive Officer. Thanks for being here, Chad. We always appreciate the time.

Chad M. Robins
Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman

Thanks, Doug, for having me. I appreciate it.

Doug Schenkel
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

So for those of you new to the story, Adaptive's immune profiling platform is well-validated and its product pipeline continues to advance with over 380 issued and 60 pending patents. I think that's what we were up to a last count, I'm sure it continues to grow. Chad and his team have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot